Topic

Blenrep (belantamab mafodotin)

A collection of 28 issues

Work With Your Doctor to Get Blenrep (belantamab mafodotin) Covered by Blue Cross Blue Shield in Pennsylvania: Provider Collaboration Guide

Answer Box: Getting Blenrep Covered in Pennsylvania Current Status: Blenrep is withdrawn from the US market until FDA review concludes (October 2025 PDUFA date). Access is limited to GSK's compassionate use program or clinical trials. Fastest Path: Work with your oncologist to apply for GSK's expanded

How to Renew Blenrep (belantamab mafodotin) Coverage with Cigna in California: Complete Timeline and Documentation Guide

Answer Box: Renewing Blenrep (belantamab mafodotin) with Cigna in California Important Note: As of July 2025, Blenrep was re-approved by the FDA for relapsed/refractory multiple myeloma in combination with bortezomib and dexamethasone (BVd). However, access requires enrollment in the REMS program due to ocular toxicity risks. For patients currently

Work With Your Doctor to Get Blenrep (belantamab mafodotin) Covered by Humana in New Jersey: Provider Collaboration Guide

Quick Answer: Getting Blenrep Coverage Through Doctor Partnership Current Status: Blenrep (belantamab mafodotin) was withdrawn from the U.S. market in 2022 and is under FDA review with a PDUFA date of October 23, 2025. Access is currently limited to clinical trials or expanded access programs. Fastest Path: Work with

Getting Blenrep (Belantamab Mafodotin) Covered by Blue Cross Blue Shield in Ohio: Current Access Options and Appeals Process

Answer Box: Your Fastest Path to Blenrep Access in Ohio Current Status: Blenrep is not commercially available but accessible through GSK's compassionate use program. Blue Cross Blue Shield in Ohio requires prior authorization for specialty drugs, with standard review taking 5-15 business days. Since Blenrep remains under FDA

How to Get Blenrep (Belantamab Mafodotin) Covered by Cigna in Illinois: Complete Timeline and Appeal Guide

Answer Box: Getting Blenrep Covered by Cigna in Illinois Current Status: Blenrep (belantamab mafodotin) received FDA approval in July 2025 for relapsed/refractory multiple myeloma after previous market withdrawal. Timeline: Cigna typically processes specialty drug prior authorizations within 1-3 business days through Express Scripts/Accredo. First Step: Work with your

Work With Your Doctor to Get Blenrep (Belantamab Mafodotin) Approved by UnitedHealthcare in Michigan: Complete Provider Collaboration Guide

Answer Box: Blenrep (belantamab mafodotin) is currently only available through GSK's compassionate use program after FDA withdrawal in 2022. UnitedHealthcare requires prior authorization for specialty oncology drugs, with 85% appeal success rates through peer-to-peer review. First step: Contact your oncologist to verify eligibility for compassionate use (4+ prior

The Complete Requirements Checklist to Get Blenrep (Belantamab Mafodotin) Covered by UnitedHealthcare in North Carolina

Answer Box: Blenrep Coverage Status Blenrep (belantamab mafodotin) has been withdrawn from the U.S. market by GSK. UnitedHealthcare will deny coverage requests for commercial Blenrep because it's no longer commercially available. However, patients may access Blenrep through GSK's compassionate use program if already enrolled in

How to Get Blenrep (Belantamab Mafodotin) Covered by Cigna in North Carolina: Complete Appeals Guide

Answer Box: Getting Blenrep Covered by Cigna in North Carolina Good news: Blenrep (belantamab mafodotin) received FDA approval in July 2025 for relapsed/refractory multiple myeloma. For Cigna coverage in North Carolina: (1) Your oncologist submits prior authorization showing you've tried at least four prior regimens, (2) If

How to Get Blenrep (Belantamab Mafodotin) Covered by Humana in New York: Complete Appeal Guide with Forms and Timelines

Answer Box: Getting Blenrep Covered by Humana in New York Current Status: Blenrep (belantamab mafodotin) was re-approved by the FDA on October 23, 2025, for relapsed/refractory multiple myeloma. Most denials occur because the drug requires REMS enrollment and specialty handling. Fastest Path to Approval: 1. Submit Humana's

Getting Blenrep (Belantamab Mafodotin) Covered by Aetna CVS Health in Georgia: Appeals Guide and External Review Process

Answer Box: Blenrep Coverage Path for Georgia Residents Blenrep (belantamab mafodotin) is currently off-market in the US (withdrawn 2022, resubmission under FDA review). For Georgia residents with Aetna CVS Health, access is limited to clinical trials or expanded access programs. If denied coverage for trial participation or compassionate use: 1.